← Eichor
Condition: Glomerular Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Glomerular Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 2 · 6 location(s) · Omeros Corporation · NCT06209736A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Phase 3 · 31 location(s) · Cerium Pharmaceuticals, Inc. · NCT05696613Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
Phase N/A · 5 location(s) · University of Michigan · NCT01016613Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa
Phase N/A · 1 location(s) · Swiss Tropical & Public Health Institute · NCT05881447Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250NEPTUNE Match Study
NA · 16 location(s) · University of Michigan · NCT04571658Integrating BIA and eGFR for Nutritional Status in Hemodialysis Patients
Phase N/A · 1 location(s) · University of Tartu · NCT06873880A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT07203404Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Phase N/A · 1 location(s) · University of Michigan · NCT05505500Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Phase 3 · 87 location(s) · Novartis Pharmaceuticals · NCT04817618The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases
NA · 1 location(s) · Meyer Children's Hospital IRCCS · NCT06325059Velocity-Based Resistance Training in Kidney Transplant Recipients
NA · 1 location(s) · Fundación Universitaria del Area Andina · NCT07370727A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Phase 2 · 23 location(s) · Akebia Therapeutics · NCT07268638Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Phase 3 · 19 location(s) · Alessandro Doria · NCT06217302Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary
Phase 3 · 6 location(s) · Novartis Pharmaceuticals · NCT07498335Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · 47 location(s) · Travere Therapeutics, Inc. · NCT05003986Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · 50 location(s) · Walden Biosciences · NCT06466135Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Phase 3 · 9 location(s) · Novartis Pharmaceuticals · NCT05795140Home Reported Outcomes in C3G Study
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07029542Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Phase 2 · 103 location(s) · Novartis Pharmaceuticals · NCT05268289Effects of Exogenous Ketosis on Proteinuria and Renal Function
NA · 1 location(s) · Gødstrup Hospital · NCT06867471Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Phase 1 · 19 location(s) · Everest Medicines (China) Co.,Ltd. · NCT05800873Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Phase 3 · 21 location(s) · Novartis Pharmaceuticals · NCT06858319Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Phase 2 · 4 location(s) · Region Skane · NCT04183101Atacicept in Multiple Glomerular Diseases
Phase 2 · 1 location(s) · Vera Therapeutics, Inc. · NCT06983028Chinese Adults With Kidney Disease
Phase 2 · 9 location(s) · ADARx Pharmaceuticals, Inc. · NCT07522099A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07416162Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clini
Phase 1/Phase 2 · 1 location(s) · PT. Prodia Stem Cell Indonesia · NCT07396155Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope o
Phase 4 · 12 location(s) · Christian Medical College, Vellore, India · NCT06676384Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Phase 3 · 53 location(s) · Novartis Pharmaceuticals · NCT03955445
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.